<DOC>
	<DOC>NCT00405249</DOC>
	<brief_summary>The purpose of this 28 day study is to assess the viral kinetics and safety of elvucitabine.</brief_summary>
	<brief_title>Safety Study of Elvucitabine in HIV-1 Subjects</brief_title>
	<detailed_description>This is a 14 day on treat/14 day off treatment randomized, double blind viral kinetic study of elvucitabine versus lamivudine administered once daily to HIV infected subjects with a documented M184V variant.</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<criteria>HIV infected, clinically stable, adults HIVRNA 5000 150,000, CD4 100 Genotypically documented M184V variant Receiving stable ART. Hep B HIV1 genotype for 4 protease inhibitors HIV1 genotype positive for 2 NNRTI mutations Previous therapy with system myelosuppressive potential within 3 months of study start Use of Epogen or Neupogen History of cirrhosis Alcohol or drug dependence Inability to tolerate oral medication Women who are pregnant or breast feeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2009</verification_date>
	<keyword>HIV-1</keyword>
	<keyword>Treatment Experienced</keyword>
</DOC>